Why Is SAREPTA THERAPEUTICS (SRPT) Stock Up Today?

Why SRPT stock is up today

Sarepta Therapeutics stock rose 9.31% to $22.89 on Wednesday as traders reacted to analyst commentary and broader market sentiment. The move came despite a broader selloff in the biotech sector following a major clinical setback by Novartis. Analysts from multiple firms reiterated their positions on Sarepta, which helped stabilize investor sentiment and triggered a rebound in the stock.

What Happened

The stock opened at $20.92 and quickly found support as analysts from H.C. Wainwright, Jefferies, and Mizuho reiterated their ratings on Sarepta. H.C. Wainwright maintained a Sell rating with a $5 price target, while Jefferies and Mizuho signaled that the recent selloff was overdone. These updates came in the wake of Novartis reporting a failed trial for its experimental drug, which led to a broad sell-off in related biotech stocks including Sarepta. Despite the negative news, Sarepta’s stock found a floor and climbed to an intraday high of $23.20 by 10:05 AM ET. The stock’s performance was also supported by a lack of major negative developments specific to Sarepta.

What The Data Shows

The stock traded on 0.9 million shares, which is 0.3 times the 3-month daily average. Sarepta remains unprofitable, with a trailing twelve-month (TTM) net margin of -6.9% and a TTM revenue decline of 20.4%. The stock has traded between $14.68 and $25.32 over the past 52 weeks and is currently near the upper end of that range. The recent 8-session price trend showed a decline of 5.0%, from $21.59 to $20.51, before today’s rebound. There were no unusual options activities or insider transactions reported in the last 90 days.

What To Watch

Sarepta Therapeutics does not have an upcoming earnings date in the immediate future. Investors should continue to monitor analyst coverage and broader sector developments, particularly in the rare disease and gene therapy space.